12:00 AM
 | 
May 28, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Adcetris brentuximab vedotin regulatory update

Seattle Genetics said Health Canada accepted for review an NDS for Adcetris brentuximab vedotin to treat relapsed Hodgkin's lymphoma and systemic anaplastic large cell lymphoma (ALCL). Seattle Genetics is seeking conditional approval for the antibody-drug conjugate (ADC) composed of an anti-...

Read the full 183 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >